Categories: News

Phemex Upgrades RPI Ecosystem, Setting New Liquidity Benchmarks Across 210+ Pairs

APIA, Samoa, Dec. 26, 2025 /PRNewswire/ — Phemex, a user-first crypto exchange, has announced a major upgrade to its Retail Price Improvement (RPI) order system. By deepening strategic ties with top-tier institutional liquidity partners, the enhanced RPI ecosystem now delivers market-leading depth that significantly outperforms industry benchmarks.

- Advertisement -

Latest data from a comprehensive market audit conducted in late 2025 reveals that the RPI upgrade has triggered a massive surge in liquidity across Phemex’s core assets. Based on internal comparative research of public order book depth (±0.1% from mid-price) relative to top-tier exchange averages:

- Advertisement -
  • BTCUSDT: Liquidity depth is now 2x the standard industry benchmark.
  • ETHUSDT: Liquidity has reached a staggering 5x the average market liquidity.
  • SOLUSDT: Liquidity has climbed to 5.5x compared to high-performance market standards.
  • Top 12 Trading Pairs: Aggregate liquidity consistently tracks at 3x the baseline of top-tier exchange requirements.

RPI orders are specifically engineered as Maker orders for retail customers (non-API manual traders). This upgrade ensures a much denser order book and more aggressive pricing, narrowing spreads and providing “price improvement” that often exceeds the visible order book.

- Advertisement -

By ensuring that RPI orders interact exclusively with the retail maker liquidity — effectively bypassing high-frequency API algorithms — Phemex’s upgraded RPI has allowed the platform to maintain a competitive edge in liquidity across more than 210 trading pairs. This reinforces Phemex’s commitment to providing a transparent and high-performance environment where retail users can trade with the same precision and execution quality as institutional giants.

- Advertisement -

About Phemex
Founded in 2019, Phemex is a user-first crypto exchange trusted by over 10 million traders worldwide. The platform offers spot and derivatives trading, copy trading, and wealth management products designed to prioritize user experience, transparency, and innovation. With a forward-thinking approach and a commitment to user empowerment, Phemex delivers reliable tools, inclusive access, and evolving opportunities for traders at every level to grow and succeed.

- Advertisement -

For more information, please visit: https://phemex.com/

- Advertisement -

Logo – https://mma.prnewswire.com/media/2819516/Phemex_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/phemex-upgrades-rpi-ecosystem-setting-new-liquidity-benchmarks-across-210-pairs-302649630.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

8 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

8 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

8 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

8 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

8 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

8 hours ago